baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Put 80 GILD 21.02.2025/ DE000JT55FR3 /

23/01/2025 09:22:24	Chg.-0.001	Bid21:41:56	Ask21:41:56	Underlying	Strike price	Expiration date	Option type
0.018EUR	-5.26%	0.018 Bid Size: 75,000	0.028 Ask Size: 75,000	Gilead Sciences Inc	80.00 USD	21/02/2025	Put

GlobeNewswire 27/08/2024 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

GlobeNewswire 08/08/2024 HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 08/08/2024 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

GlobeNewswire 08/08/2024 Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

GlobeNewswire 06/08/2024 MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results

GlobeNewswire 05/08/2024 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 05/08/2024 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

GlobeNewswire 01/08/2024 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire 23/07/2024 ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...

GlobeNewswire 15/07/2024 Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...

GlobeNewswire 08/07/2024 Memo Therapeutics AG appoints Paul Carter as Chairperson

GlobeNewswire 04/07/2024 Burns McClellan Mourns the Passing of Founder and CEO, Lisa Burns

GlobeNewswire 01/07/2024 HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...

GlobeNewswire 01/07/2024 Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...

GlobeNewswire 28/06/2024 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

GlobeNewswire 26/06/2024 Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs

GlobeNewswire 26/06/2024 Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors

TeleTrader 20/06/2024 US opens mostly higher after labor, housing data

GlobeNewswire 18/06/2024 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...

GlobeNewswire 17/06/2024 Assembly Biosciences Announces $12.6 Million in Equity Financings

GlobeNewswire 10/06/2024 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...

GlobeNewswire 22/05/2024 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...

GlobeNewswire 14/05/2024 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

JP Morgan Put 80 GILD 21.02.2025/ DE000JT55FR3 /

If you wish to receive reply to your feedback, please provide your email address.